Evaluation and efficacy of SGLT2 inhibitors in diabetes mellitus and heart failure patients in telangana
Abstract
Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which were initially created as antihyperglycemic drugs for type 2 diabetes mellitus, have shown remarkable cardiovascular and renal advantages. Drugs like empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin inhibit glucose reabsorption in the proximal renal tubules, enhancing glycosuria and decreasing plasma glucose. In addition to glycemic control, these agents have impressive cardioprotective actions through enhanced left ventricular function, decreased heart failure hospitalization, and cardiovascular death. By causing natriuresis and osmotic diuresis, they reduce blood pressure and cardiac load, improving overall cardiac efficiency.
Methods: This a prospective and observational study was conducted over a period of six months in OP department and patient relevant data were collected from the patient case sheet in cardiology department at a tertiary care hospital in Telangana . The data collection form was prepared and used. The data collection form contains demographic details like age , gender, socioeconomic factors ,past history ,laboratory diagnosis like BP, FBS, PBS, 2D -ECHO. Statistical analysis was done by using chi square test a p-value of <0.001indicating significance.
Results: The study population consisted predominantly of males (69.09%), with the highest prevalence in the 42–51 age group (30.9%). HF Class 2 was the most common (57.7%). A significant proportion (71.8%) had diabetes, and…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.